Abacus Bioscience, Inc.

Pre-clinical immunotherapeutic drug development for cancer and antiviral diseases using a CD180 backbone

Abacus Bioscience, established in 2015 by Alan Wahl, serving as CEO, and Che-Leung Law, the Chief Scientific Officer, focuses on developing innovative immunotherapies. Originating from the University of Washington, the company employs a method that addresses tumor antigens to activate a significant immune reaction, aiming for advancements in cancer treatment and chronic infection management. Their research includes potential applications against viruses, such as Hepatitis B. With a foundation built on solid scientific principles and driven by a team with a track record at Seagen, Abacus Bioscience secured $4.4 million in initial funding to advance its research initiatives. replica relojes